ReviewNature cancer2020
Discovery through clinical sequencing in oncology.
Review in Nature cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Advances in Microfluidic Single-Cell RNA Sequencing and Spatial Transcriptomics.Micromachines · 2025Review
- Basket Trials: Past, Present, and Future.Annual review of cancer biology · 2024Article
- Toward Informed Selection and Interpretation of Clinical Genomic Tests in Prostate Cancer.JCO precision oncology · 2024Article
- Insights for precision oncology from the integration of genomic and clinical data of 13,880 tumors from the 100,000 Genomes Cancer Programme.Nature medicine · 2024Article
- Editorial: Novel immune markers and predictive models for immunotherapy and prognosis in breast and gynecological cancers.Frontiers in immunology · 2024Article
- T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome.Nature reviews. Drug discovery · 2023Review
- Lessons learnt, and still to learn, in first in human stem cell trials.Stem cell reports · 2023Review
- New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Article
- Effective and Efficient Delivery of Genome-Based Testing-What Conditions Are Necessary for Health System Readiness?Healthcare (Basel, Switzerland) · 2022Article
- The mutational signatures of formalin fixation on the human genome.Nature communications · 2022Article
- Immune inactivation by neuropilin-1 predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.Cancer immunology, immunotherapy : CII · 2022Article
- Comparing Survival Outcomes for Advanced Cancer Patients Who Received Complex Genomic Profiling Using a Synthetic Control Arm.Targeted oncology · 2022Article
- Computational methods and translational applications for targeted next-generation sequencing platforms.Genes, chromosomes & cancer · 2022Review
- Harnessing multimodal data integration to advance precision oncology.Nature reviews. Cancer · 2022Review
- Editorial: The application of sequencing technologies and bioinformatics methods in cancer biology.Frontiers in cell and developmental biology · 2022Article
- Are we there yet? A machine learning architecture to predict organotropic metastases.BMC medical genomics · 2021Article
- A pan-cancer fingerprint: common molecular denominators of the human tumor microenvironment.Signal transduction and targeted therapy · 2021Article
- Tilting MYC toward cancer cell death.Trends in cancer · 2021Review
- Overcoming therapy resistance in EGFR-mutant lung cancer.Nature cancer · 2021Review
- An international virtual hackathon to build tools for the analysis of structural variants within species ranging from coronaviruses to vertebrates.F1000Research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The molecular characterization of tumors now informs clinical cancer care for many patients. This advent of molecular oncology has been driven by the expanding number of therapeutic biomarkers that can predict sensitivity to both approved agents and investigational agents. Beyond its role in driving clinical-trial enrollments and guiding therapy in individual patients, large-scale clinical genomics in oncology also represents a rapidly expanding research resource for translational scientific discovery. Here we review the progress, opportunities, and challenges of scientific and translational discovery from prospective clinical genomic screening programs now routinely conducted for patients with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.